A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 2042-2048

  Wong, R ^a   Cunningham, D ^a   Barbachano, Y ^a   Saffery, C ^a   Valle, J ^b   Hickish, T ^c   Mudan, S ^a   Brown, G ^a   Khan, A ^a   Wotherspoon, A ^a   Strimpakos, A S ^a   Thomas, J ^a   Compton, S ^a   Chua, Y J ^a   Chau, I ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Bevacizumab; Capecitabine; Colorectal cancer; Liver metastases; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN; RALTITREXED;

ADULT; AGED; ANASTOMOSIS LEAKAGE; ANEMIA; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL LIVER ONLY METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INFECTION; LETHARGY; LIVER FAILURE; LIVER FUNCTION; LIVER METASTASIS; LIVER RESECTION; LUNG EMBOLISM; MALE; METASTASIS RESECTION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERICARDITIS; PERIOPERATIVE PERIOD; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIOFREQUENCY ABLATION; SIDE EFFECT; SURGICAL INFECTION; SURGICAL MORTALITY; THORAX PAIN; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

EID: 79959947067     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq714     Document Type: Article

References (33)

1. Fernandez FG, Drebin JA, Linehan DC et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-447.
2. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016.
3. Sanoff HK, Sargent DJ, Campbell ME et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26: 5721-5727.
4. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-657.
5. Adam R, Wicherts DA, de Haas RJ et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27: 1829-1835.
6. Masi G, Loupakis F, Pollina L et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009; 249: 420-425.
7. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-1319.
8. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
9. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
10. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
11. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
12. Okines A, Puerto OD, Cunningham D et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-1038.
13. Cassidy J, Clarke S, Diaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
14. Nordlinger B, Van Cutsem E, Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 20: 985-992.
15. Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-1262.
16. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.
17. Giacchetti S, Itzhaki M, Gruia G et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-669.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
19. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med 2001; 20: 859-866.
20. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Stang A, Fischbach R, Teichmann W et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009; 45: 1748-1756.
22. Folprecht G, Gruenberger T, Bechstein WO et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47.
23. Watkins DJ, Chau I, Cunningham D et al. Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. Br J Cancer 2010; 102: 255-261.
24. de Haas RJ, Wicherts DA, Flores E et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg 2008; 248: 626-637.
25. Adam R, Wicherts DA, de Haas RJ et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol 2008; 26: 1635-1641.
26. Blazer DG III, Kishi Y, Maru DM et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344-5351.
27. Chun YS, Vauthey JN, Boonsirikamchai P et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009; 302: 2338-2344.
28. Wong R, Cunningham D. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol 2008; 26: 5668-5670.
29. Hurwitz HI, Yi J, Ince W et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009; 14: 22-28.
30. Kesmodel SB, Ellis LM, Lin E et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 2008; 26: 5254-5260.
31. Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835.
32. Sugrue M, Kozloff M, Hainsworth J et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 2006; 24: 3535. (Meeting Abstracts).
33. Chau I, Cunningham D. Bevacizumab-associated gastrointestinal perforation. Lancet Oncol 2009; 10: 534-536.